HPTN 083: Updated Safety and Efficacy of Long-Acting Injectable CAB vs Daily Oral FTC/TDF as HIV PrEP in MSM and TGW

Source: Conference Coverage of CROI 2022: Clinical Impact of New HIV Data*
Download Slideset
February 13-16, 2022; Virtual
Additional 1 year of unblinded follow-up of HPTN 083 study continues to support superiority of long-acting injectable cabotegravir vs daily oral FTC/TDF in reducing incident HIV infection among MSM and TGW at high risk of HIV infection.
Format: Microsoft PowerPoint (.ppt)
File Size: 326 KB
Released: February 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Cepheid
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings